(UroToday.com) As part of the “Game-changing Session 2” plenary presentation at the European Association of Urology (EAU) Virtual Annual Meeting, Dr. Grimm presented an analysis of the recurrence risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ stratified for European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urology Association for Oncological Treatment (CUETO) risk categories.